December 21, 2017 / 6:05 AM / a month ago

BRIEF-Ablynx Announces Positive Data From Japanese Ethno-Bridging Study Of Caplacizumab

Dec 21 (Reuters) - ABLYNX NV:

* ABLYNX ANNOUNCES POSITIVE DATA FROM ITS JAPANESE ETHNO-BRIDGING STUDY OF CAPLACIZUMAB

* COMPARABLE PHARMACOKINETICS (PK) OBSERVED IN JAPANESE AND CAUCASIAN HEALTHY VOLUNTEERS

* CAPLACIZUMAB WAS WELL-TOLERATED IN ALL GROUPS

* SINGLE AND MULTIPLE DOSE PHASE I STUDY DEMONSTRATED COMPARABLE PK OF CAPLACIZUMAB IN JAPANESE AND CAUCASIAN SUBJECTS Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below